Teclistamab Demonstrates Promising Efficacy, Safety in Relapsed/Refractory Multiple Myeloma
Treatment with a subcutaneous formulation of teclistamab, a novel bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 receptors, was well tolerated and associated...
Melphalan Flufenamide Withdrawn From U.S. Market
Oncopeptides AB has announced its decision to withdraw melphalan flufenamide from the U.S. market after results from the phase III OCEAN study showed an...
Evaluating Venetoclax Plus Daratumumab and Dexamethasone in Relapsed/Refractory MM
Treatment with oral BCL-2 inhibitor venetoclax induced deep and durable responses in patients with relapsed or refractory multiple myeloma (MM), especially those with t(11;14)...
Daratumumab and Hyaluronidase-fihj Combination Approved for Relapsed/Refractory MM
The FDA has approved daratumumab and hyaluronidase-fihj, in combination with pomalidomide and dexamethasone (Pd), for the treatment of patients with relapsed or refractory MM....
ALLO-605 Receives FDA Fast Track Designation for Relapsed/Refractory MM
The U.S. Food and Drug Administration (FDA) has granted fast track designation to ALLO-605 for the treatment of adult patients with relapsed or refractory...
FDA Warns of Increased Death Risk for Patients with MM Receiving Melphalan Flufenamide
The OCEAN study evaluating melphalan flufenamide and dexamethasone for the treatment of patients with multiple myeloma (MM) found an increased risk of death, according...
Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma
While treatment with ixazomib, lenalidomide, and dexamethasone (ixazomib-Rd) was shown to improve progression-free survival, recent long-term findings from the phase III TOURMALINE-MM1 trial published...
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM
Recent results suggest that in patients with relapsed multiple myeloma (MM), combination therapy consisting of carfilzomib and dexamethasone (Kd) plus isatuximab is associated with...
Deep and Durable Responses Seen With CAR T-Cell Therapy for Pretreated Myeloma
In preliminary efficacy results, treatment with a single low-dose infusion of ciltacabtagene autoleucel (cilta-cel) led to early, deep, and durable responses in patients with...
Does Rheumatic Disease Increase Risk of MGUS Progression to Hematologic Malignancies?
Patients with monoclonal gammopathy of undetermined significance (MGUS) and concomitant non-antibody (Ab)–mediated inflammatory rheumatic diseases are at increased risk of progression to overt multiple...
Current Issue
November 2021 Bonus ASH Annual Meeting Preview Edition
This issue offers a behind-the-scenes look at this year's annual meeting, and more.